Stueve Siegel Hanson Investigates Taxotere

Stueve Siegel Hanson is investigating the prescription drug Taxotere                    

Taxotere Label

 

which the FDA reports is known to cause permanent hair loss in some women. Taxotere is one of two major chemo drug used in breast cancer treatment.  While most women should get their hair back after their last chemo treatment, studies show that 9% of women, even as high as 20%, will be affected with permanent alopecia (hair loss) after using Taxotere.

Taxotere is manufactured by Sanofi-Aventis, a multinational pharmaceutical company headquartered in France and one of the largest pharmaceutical companies in the world.  According to one law suit filed, Sanofi-Aventis knew as early as 2005 that the drug may cause permanent alopecia in as many as 9% of Taxotere patients and intentionally withheld this information from the medical community and the public.

The race for profitability may have contributed to this adverse reaction.  In the 1960’s and 1970’s, pharmaceutical companies competed to develop a drug to stop cell division which was a monumental step forward in the treatment of cancer.  When a competitor beat Sanofi-Aventis in the discovery, the drug maker reacted by increasing the potency of Taxotere. In the 1990’s, the FDA warned Sanofi-Aventis that the drug was too potent and made women sick.  Sanofi rebranded the drug saying it was “more effective at eradicating cancer” than its leading competitor. The FDA gave approval for Taxotere in 1996.

Many clinicians have moved away from prescribing Taxotere because  certain studies warned about the side effects. In 2009, the FDA informed Sanofi that it “cannot make misleading statements suggesting Taxotere is superior just because it is twice as potent.” In 2015, Sanofi-Aventis updated its warning labels to include “permanent and irreversible alopecia.” But this warning was inadequate. Today, the drug maker provides a warning label that reads “Adverse Reactions. Cases of permanent alopecia have been reported.”

If you or someone you know was treated for breast cancer by Taxotere and has experienced major hair loss and wish to receive additional information about your legal options, please call 866-714-0873 to speak to one of our female attorneys or fill out the form on this page. 

  • Our pick for bet-the-company litigation

    - CEO, Heartland Spine & Specialty Hospital
  • Stueve Siegel Hanson 'beats the big guys in court'

    - Modern Healthcare covering SSH landmark anti-trust case
  • Big firm lawyers, small firm service.

    – President – Overlap, Inc.
  • Best of the Bar

    – Kansas City Business Journal
  • One of the best plaintiff’s lawyers in the country.

    – Lawdragon Magazine

Contact Us

success

AWARDS & RECOGNITION

  • Benchmark Plaintiff

    Benchmark Plaintiff

  • Commercial Litigation

    Commercial Litigation

  • Super Lawyers 2015

    Super Lawyers 2015

  • Best Lawyers

    Best Lawyers

The information you obtain at this site is not, nor is it intended to be, legal advice. You should consult an attorney for advice regarding your individual situation. We invite you to contact us and welcome your calls, letters and electronic mail. Contacting us does not create an attorney-client relationship. Please do not send any confidential information to us until such time as an attorney-client relationship has been established.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.